arrow
S

Stephen J. Forman

city of hope
H指数:127
被引数:6.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Health status impairments in tyrosine kinase inhibitor-treated chronic myeloid leukemia patients versus blood or marrow transplant survivors and non-cancer controls

酪氨酸激酶抑制剂治疗的慢性髓性白血病患者的健康状况受损情况与血液或骨髓移植幸存者及非癌症对照者的比较

Leukemia
IF13.4
2026-08-210
OAAI
Whole-protein screening and multi-modal profiling of antigen-specific CD4+ T cells at single-cell resolution

全蛋白质筛选和多模态分析抗原特异性CD4+ T细胞在单细胞分辨率

2026-05-120
OAAI
Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy

白血病患者接受CD19 CAR T细胞治疗后的长期应答的免疫代谢决定因素

2026-02-200
OAAI
Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis

异基因造血干细胞移植(allo-HCT)在采用氟达拉滨/美法仑(Fludarabine/Melphalan)预处理和他克莫司/西罗莫司(Tacrolimus/Sirolimus)移植物抗宿主病(GVHD)预防方案的急性髓系白血病(AML)中的长期生存结局。

2025-11-180
OAAI
CTIM-07. A PHASE 1 STUDY OF INTRAVENTRICULARLY ADMINISTERED AUTOLOGOUS HER2-TARGETING CHIMERIC ANTIGEN RECEPTOR T CELLS (HER2-CAR T CELLS), WITH AND WITHOUT LYMPHODEPLETION, IN HER2-POSITIVE BREAST CANCER PATIENTS WITH RECURRENT BRAIN AND/OR LEPTOMENINGEAL METASTASES

CTIM-07。一项I期研究,评估经脑室内给药的自体HER2靶向嵌合抗原受体T细胞(HER2-CAR T细胞),在伴或不伴淋巴细胞清除的情况下,用于HER2阳性乳腺癌患者复发脑和/或软脑膜转移的疗效。

2025-11-110
OA
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration

Polatuzumab vedotin在CNS淋巴瘤中的应用:关于血脑屏障穿透的可行性研究

2025-10-100
OAAI
Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery

靶向PD-L1的融合蛋白工程化改造的实体瘤CAR-T细胞,用于局部IL-12递送

2025-10-010
OAAI
Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML

在IDH-2突变急性髓系白血病异基因造血细胞移植后使用enasidenib维持治疗的试验

2025-09-190
PRE
The Impact of Cytoreduction on Blinatumomab Outcomes for Relapsed or Refractory B-ALL With High Disease Burden

细胞减灭术对高肿瘤负荷复发或难治性B-ALL患者博纳吐莫单抗疗效的影响

2025-09-090
PRE
The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia

靶向治疗和免疫疗法在TP53突变急性淋巴细胞白血病患者中的疗效

2025-09-010
PRE
Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: Interim clinical experience demonstrating feasibility and safety

氯毒素靶向的CAR T细胞疗法治疗复发性胶质母细胞瘤:中期临床经验表明其可行性和安全性

2025-08-150
PREAI
Clonal hematopoiesis and risk of nonmyeloid subsequent malignant neoplasms after autologous hematopoietic cell transplantation

克隆性造血与自体造血干细胞移植后非髓系继发性恶性肿瘤的风险

2025-08-010
OAAI
The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission

成人B细胞前体急性淋巴细胞白血病患者在可测量微小残留病阴性缓解状态下,将blinatumomab巩固治疗整合到CALGB 10403方案中。

2025-06-100
PRE